Syndax Pharmaceuticals Inc

SNDX

NASDAQ. Currency in USD

23.37 -1.05 ( -4.30% )

Real time prices: December 19

Market Cap.
1.59B
Beta (5Y monthly)
1.13
Price/Earnings
-
EPS (TTM)
-0.02
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
860,591
1y Target Est.
33.14
Day's Range
22.83
-
24.29
52 Week's Range
13.27
-
26.51

Historical Summary

Performance
EPS growth
Share Buybacks

About Syndax Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.syndax.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
49.39M
Employees
59
Address
35 Gatehouse Drive, Waltham, MA, United States, 02451
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Latest news

Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should Know
Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should Know

The consensus price target hints at a 44.7% upside potential for Syndax (SNDX). While empirical...
By Zacks Investment Research - 5 weeks ago

Here's What Could Help Syndax (SNDX) Maintain Its Recent Price Strength
Here's What Could Help Syndax (SNDX) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend,...
By Zacks Investment Research - 5 weeks ago

Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with...
By Zacks Investment Research - 7 weeks ago

What Makes Syndax (SNDX) a Good Fit for 'Trend Investing'
What Makes Syndax (SNDX) a Good Fit for 'Trend Investing'

Syndax (SNDX) made it through our "Recent Price Strength" screen and could be a great...
By Zacks Investment Research - 8 weeks ago

Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?
Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 39.1% upside potential for Syndax (SNDX). While empirical...
By Zacks Investment Research - 8 weeks ago

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should...
By Zacks Investment Research - 9 weeks ago

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for...
By Zacks Investment Research - 9 weeks ago